32.49
5.96%
-2.06
Surmodics, Inc. stock is currently priced at $32.49, with a 24-hour trading volume of 87,379.
It has seen a -5.96% decreased in the last 24 hours and a +20.51% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $34.31 pivot point. If it approaches the $31.70 support level, significant changes may occur.
Previous Close:
$34.55
Open:
$35.21
24h Volume:
87,379
Market Cap:
$462.53M
Revenue:
$138.20M
Net Income/Loss:
$5.52M
P/E Ratio:
-19.69
EPS:
-1.65
Net Cash Flow:
$9.86M
1W Performance:
+24.15%
1M Performance:
+20.51%
6M Performance:
+4.64%
1Y Performance:
+41.14%
Surmodics, Inc. Stock (SRDX) Company Profile
Name
Surmodics, Inc.
Sector
Industry
Phone
952-500-7000
Address
9924 West 74th Street, Eden Prairie, MN
Surmodics, Inc. Stock (SRDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-13-23 | Upgrade | Needham | Hold → Buy |
Feb-13-23 | Downgrade | Needham | Buy → Hold |
Jul-23-20 | Upgrade | Needham | Hold → Buy |
Dec-11-19 | Downgrade | Needham | Buy → Hold |
Nov-01-19 | Downgrade | Lake Street | Buy → Hold |
Aug-01-19 | Reiterated | Needham | Buy |
May-02-19 | Reiterated | Lake Street | Buy |
May-02-19 | Reiterated | Needham | Buy |
Feb-21-19 | Reiterated | Needham | Buy |
May-16-18 | Reiterated | Needham | Buy |
Mar-01-18 | Upgrade | Sidoti | Neutral → Buy |
Feb-28-18 | Reiterated | Lake Street | Buy |
Feb-28-18 | Initiated | Needham | Buy |
Jul-14-17 | Initiated | Lake Street | Buy |
Nov-21-16 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Oct-06-16 | Downgrade | Sidoti | Buy → Neutral |
May-03-16 | Reiterated | Barrington Research | Outperform |
Aug-06-15 | Reiterated | Barrington Research | Outperform |
Mar-27-15 | Initiated | Dougherty & Company | Buy |
Feb-25-14 | Initiated | Laidlaw | Buy |
Aug-01-13 | Upgrade | Feltl & Co. | Buy → Strong Buy |
Nov-12-12 | Reiterated | Barrington Research | Outperform |
View All
Surmodics, Inc. Stock (SRDX) Latest News
Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
Zacks Investment Research
SurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks Investment Research
SurModics (SRDX) Q2 Earnings and Revenues Top Estimates
Zacks Investment Research
Can the 4 Medical Device Stocks Hit Targets This Earnings Season?
Zacks Investment Research
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks Investment Research
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
Zacks Investment Research
Surmodics, Inc. Stock (SRDX) Financials Data
Surmodics, Inc. (SRDX) Revenue 2024
SRDX reported a revenue (TTM) of $138.20 million for the quarter ending December 31, 2023, a +35.65% rise year-over-year.
Surmodics, Inc. (SRDX) Net Income 2024
SRDX net income (TTM) was $5.52 million for the quarter ending December 31, 2023, a +117.09% increase year-over-year.
Surmodics, Inc. (SRDX) Cash Flow 2024
SRDX recorded a free cash flow (TTM) of $9.86 million for the quarter ending December 31, 2023, a +140.15% increase year-over-year.
Surmodics, Inc. (SRDX) Earnings per Share 2024
SRDX earnings per share (TTM) was $0.38 for the quarter ending December 31, 2023, a +116.38% growth year-over-year.
Surmodics, Inc. Stock (SRDX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
KNIGHT SUSAN E | Director |
Feb 05 '24 |
Option Exercise |
23.95 |
3,932 |
94,171 |
36,267 |
DANTZKER DAVID | Director |
Jan 19 '24 |
Option Exercise |
23.95 |
3,932 |
94,171 |
40,094 |
KALICH RONALD B SR | Director |
Dec 27 '23 |
Option Exercise |
23.95 |
3,932 |
94,171 |
38,529 |
Stich Joseph J. | SVP HR and IVD |
Nov 15 '23 |
Option Exercise |
23.95 |
17,121 |
410,048 |
72,433 |
OLSON CHARLES W | SVP, Medical Device Coatings |
Nov 15 '23 |
Option Exercise |
23.95 |
12,841 |
307,542 |
58,937 |
About Surmodics, Inc.
Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Cap:
|
Volume (24h):